StreetAlpha.app
Home › Stocks › RIGL

Rigel Pharmaceuticals Inc (RIGL)

$42.92
▼ −1.85%
LAST CLOSE · NOV 17

Rigel is a South San Francisco biotechnology company that develops and sells medicines for blood disorders and cancer. It last closed at $42.92 on Nov 17, down 1.85% on the day. The average 12-month price target from 3 analysts is $63.33 (+47.6% from the last close), with a high of $86.00 and a low of $47.00. Analyst consensus is Buy, based on the latest ratings from 3 firms (2 buy, 1 hold, 0 sell).

AI Auto Pilots
Is RIGL in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$288.2M
+2.2% vs a year ago
Net income
$307.2M
+171.1% vs a year ago
EPS (diluted)
$16.07
+159.6% vs a year ago
Gross margin
89.6%
$258.3M gross profit
Valuation
Market cap
$808.2M
18.8M shares
P/E
2.7
Price over 12 month EPS
Price to sales
2.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$46.6M
At Sep 30
Shareholder equity
$445.1M
Shares outstanding
18.8M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $149.2M$149.2MFY2021FY2022: $120.2M$120.2MFY2022FY2023: $116.9M$116.9MFY2023FY2024: $179.3M$179.3MFY2024FY2025: $294.3M$294.3MFY2025

From RIGL's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
3firms
2 Buy1 Hold0 Sell
Each firm's latest rating on RIGL in the past 90 days
Average 12-month target
$63.33
▲ 47.6% upside

Based on 3 analysts who set a price target on RIGL in the past 90 days. The average target is $63.33, with a high of $86.00 and a low of $47.00, compared with the last close of $42.92.

Low $47.00Avg $63.33High $86.00
Blue marker: last close $42.92
Highest target$86.00
Average target$63.33
Lowest target$47.00
Latest rating changes
CitigroupMaintained
Nov 9Buy$86
Cantor FitzgeraldMaintained
Nov 6Hold$47
HC Wainwright & Co.Target lowered
Sep 25Buy$85 → $57
Piper SandlerMaintained
Aug 17Hold$49
HC Wainwright & Co.Target raised
Aug 14Buy$57 → $85
DateFirmActionRatingPrice target
Nov 9CitigroupMaintainedBuy$86
Nov 6Cantor FitzgeraldMaintainedHold$47
Sep 25HC Wainwright & Co.Target loweredBuy$85 → $57
Aug 17Piper SandlerMaintainedHold$49
Aug 14HC Wainwright & Co.Target raisedBuy$57 → $85
Loading…

Technical Analysis

RIGL · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend

The stock is 10% below its 20 day and 10% below its 50 day average. It is 12% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 41). The nearest support is the Pivot at $42.83, and the nearest resistance the swing high (Jul 16) at $43.34.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 5.6%/day
Key levels
$52.6152 week high+22.6%
$47.2550 day average+10.1%
$47.1620 day average+9.9%
$44.64100 day average+4.0%
$43.57Pivot R1+1.5%
$43.34Swing high (Jul 16)+1.0%
$42.92Last close
$42.83Pivot−0.2%
$42.19Pivot S1−1.7%
$37.66200 day average−12.3%
$37.60Swing low (Nov 6)−12.4%
$24.9552 week low−41.9%
Indicators
RSI (14)40.89Middle of its rangeNeutral
MACD-1.20Below its signal lineBearish
Stochastic40.7Middle of its rangeNeutral
ADX (14)22.4Weak trend
Williams %R-64.6Oversold below −80, overbought above −20Neutral
CCI (20)-89.8Oversold below −100, overbought above 100Neutral
Rate of change−12.2%Change over 10 sessionsBearish
ATR (14)$2.41Typical daily range, 5.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for RIGL

What happened before

See how RIGL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow RIGL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How RIGL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in RIGL in the last 90 days.

Loading…

See today’s whale options flow across the market →

RIGL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲94 buying vs 67 selling
  • ▲Held by funds +6.9 pts
  • ▲Funds holding +13
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding170157+8.3%
In funds' top 1032+50.0%
Held by funds93.9%87.0%+6.9 pts
New / increased32 / 6232 / 52+11.9%
Reduced / sold out49 / 1856 / 26−18.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RIGL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RIGL is in one of them and how their past RIGL trades turned out.

RIGL in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RIGL in an article yet. Here's the latest on the wider market.

About Rigel Pharmaceuticals

Rigel is a biotechnology company based in South San Francisco, California, that develops and sells medicines for patients with blood disorders and cancer. Its approved products include TAVALISSE, an oral medicine for adults with chronic immune thrombocytopenia, REZLIDHIA for certain adults with relapsed or refractory acute myeloid leukemia, and GAVRETO for certain lung and thyroid cancers. The company is also developing other treatments, including an experimental drug for a blood disorder called myelodysplastic syndrome.

Headquarters
South San Francisco, CA